---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-067026"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:40:04.382319+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M

## Summary
- Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.
- Full-year 2025 net loss $58.8M vs $90.9M; adjusted EBITDA loss $62.6M vs $64.2M.
- FY2026 revenue guidance $80-85M; company expects seasonality similar to prior years.
- Cash and investments from continuing ops $210.7M at Dec 31, 2025; ~$550M after SomaLogic close on Jan 30, 2026.
- Approximately $1 billion in U.S. federal NOL carryforwards available; usage may be limited.

## SEC filing metadata
- accession: 0001193125-26-067026
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/0001193125-26-067026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000119312526067026/lab-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-067026
- JSON: https://secwatch.observer/filing/0001193125-26-067026.json
- Plain text: https://secwatch.observer/filing/0001193125-26-067026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.